| Gene symbol | CFB | Synonyms | AHUS4, ARMD14, BF, BFD, CFAB, CFBD, FB, FBI12, GBG, H2-Bf, PBF2 | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | complement factor B | ||||
| GTO ID | GTC2050 |
| Trial ID | NCT03815825 |
| Disease | Macular Degeneration |
| Altered gene | CFB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | IONIS-FB-LRx |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) |
| Year | 2019 |
| Country | Australia|Austria|Canada|Czechia|Netherlands|New Zealand|Poland|Spain|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 696844-CS5|2020-005174-94 |
| Vector information | |||
|
|||
| Cohort1: IONIS-FB-LRx | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||